35
Atherosclerosis, 34 (1979) 35-39 @ Elsevier/North-Holland Scientific Publishers, Ltd.
THE EFFECT OF /3-PYRIDYLCARBINOL ON LIPOPROTEIN LIPIDS IN PRIMARY TYPE IIa HYPERLIPOPROTEINEMIA P. SCHWANDT, P. WEISWEILER and G. NEUREUTHER 2nd Medical Clinic, Klinikum Grosshadern, D-8000 Munich 70 (F. R.G.)
Uniuersity of Munich, Marchioninistr.
15,
(Received 15 February, 1979) (Revised, received 28 May, 1979) (Accepted 30 May, 1979)
summary The effect of long-term treatment over 6 months with P-pyridylcarbinol on the lipoprotein lipids was investigated in 12 patients with primary type IIa hyperlipoproteinemia. VLDL, LDL and HDL were separated by preparative ultracentrifugation. There was a significant decrease of serum cholesterol and phospholipids. The normal serum triglycerides were unaffected. While VLDL and HDL lipids showed no significant alterations, the LDL lipids decreased. The atypical lipid composition of the LDL was changed towards normal. Though there was a significant decrease of the “atherogenic” LDL/HDL-lipid ratios after 6 months treatment, /3-pyridylcarbinol did not result in a normalization of this ratio. Key words:
Hyperlipoproteinemia
type IIa -Lipoprotein
lipids - P-Pyridylcarbinol
Introduction The world-wide debate on the benefit-risk analysis of treating hyperlipoproteinemias by drugs includes the postulation for a more detailed knowledge of the action of drugs not only on plasma but also on lipoprotein lipids. There are only few reports on the short-term effects of nicotinic acid on serum lipoproteins and controversial data on the triglyceride lowering effect [l-7]. Therefore we studied the effect of /3-pyridylcarbinol on very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high density lipoproteins (HDL) lipids in primary type IIa hyperlipoproteinemia after 6 months treatment.
36
Materials and Methods Twelve outpatients with primary type IIa hyperlipoproteinemia according to the WHO criteria [S] completed the study. The 6 males and 6 females had a mean age f SEM of 51 + 5 years (range 36-66) and constant weight several months before and throughout the trial (Broca index 90.3 + 6.1%). The patients were accustomed to a diet poor in cholesterol (
Atherosclerosis, 34 (1979) 35-39 @ Elsevier/North-Holland Scientific Publishers, Ltd.
THE EFFECT OF /3-PYRIDYLCARBINOL ON LIPOPROTEIN LIPIDS IN PRIMARY TYPE IIa HYPERLIPOPROTEINEMIA P. SCHWANDT, P. WEISWEILER and G. NEUREUTHER 2nd Medical Clinic, Klinikum Grosshadern, D-8000 Munich 70 (F. R.G.)
Uniuersity of Munich, Marchioninistr.
15,
(Received 15 February, 1979) (Revised, received 28 May, 1979) (Accepted 30 May, 1979)
summary The effect of long-term treatment over 6 months with P-pyridylcarbinol on the lipoprotein lipids was investigated in 12 patients with primary type IIa hyperlipoproteinemia. VLDL, LDL and HDL were separated by preparative ultracentrifugation. There was a significant decrease of serum cholesterol and phospholipids. The normal serum triglycerides were unaffected. While VLDL and HDL lipids showed no significant alterations, the LDL lipids decreased. The atypical lipid composition of the LDL was changed towards normal. Though there was a significant decrease of the “atherogenic” LDL/HDL-lipid ratios after 6 months treatment, /3-pyridylcarbinol did not result in a normalization of this ratio. Key words:
Hyperlipoproteinemia
type IIa -Lipoprotein
lipids - P-Pyridylcarbinol
Introduction The world-wide debate on the benefit-risk analysis of treating hyperlipoproteinemias by drugs includes the postulation for a more detailed knowledge of the action of drugs not only on plasma but also on lipoprotein lipids. There are only few reports on the short-term effects of nicotinic acid on serum lipoproteins and controversial data on the triglyceride lowering effect [l-7]. Therefore we studied the effect of /3-pyridylcarbinol on very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high density lipoproteins (HDL) lipids in primary type IIa hyperlipoproteinemia after 6 months treatment.
36
Materials and Methods Twelve outpatients with primary type IIa hyperlipoproteinemia according to the WHO criteria [S] completed the study. The 6 males and 6 females had a mean age f SEM of 51 + 5 years (range 36-66) and constant weight several months before and throughout the trial (Broca index 90.3 + 6.1%). The patients were accustomed to a diet poor in cholesterol (
